Versartis Obtains $21,000,000 Series B Financing Round
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=8014cbf6-b7cd-47b5-ad14-53d1f99f3349&Preview=1 - Date
2/16/2011 - Company Name
Versartis - Mailing Address
500 Ellis Street Mountain View, CA 94043 - Company Description
Versartis is developing new therapeutic proteins utilizing the novel half-life extension technology, XTEN. Versartis has licensed the rights to three products (VRS-826, VRS-859, and VRS-317) from Amunix. - Website
http://www.versartis.com - Transaction Type
Venture Equity - Transaction Amount
$21,000,000 - Transaction Round
Series B - Proceeds Purposes
Versartis plans to use the proceeds primarily to conduct clinical trials of its lead product, VRS-317, for growth hormone deficiency (GHD) in both adult and pediatric patients. - M&A Terms
- Venture Investor
New Leaf Venture Partners - Venture Investor
Advent Venture Partners - Venture Investor
Index Ventures - Venture Investor
Undisclosed
